Premium
Oncogenic and tumor suppressive roles of polo‐like kinases in human hepatocellular carcinoma
Author(s) -
Pellegrino Rossella,
Calvisi Diego F.,
Ladu Sara,
Ehemann Volker,
Staniscia Tommaso,
Evert Matthias,
Dombrowski Frank,
Schirmacher Peter,
Longerich Thomas
Publication year - 2010
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23467
Subject(s) - polo like kinase , plk1 , biology , cancer research , cell cycle , kinase , oncogene , gene silencing , tumor suppressor gene , cell growth , liver cancer , cancer , hepatocellular carcinoma , carcinogenesis , microbiology and biotechnology , gene , genetics
Polo‐like kinase (PLK) proteins play critical roles in the control of cell cycle progression, either favoring or inhibiting cell proliferation, and in DNA damage response. Although either overexpression or down‐regulation of PLK proteins occurs frequently in various cancer types, no comprehensive analysis on their function in human hepatocellular carcinoma (HCC) has been performed to date. In the present study, we define roles for PLK1, PLK2, PLK3, and PLK4 during hepatocarcinogenesis. Levels of PLK1, as assessed by means of real‐time reverse‐transcription PCR and western blot analysis, were progressively increased from nonneoplastic surrounding liver tissues to HCC, reaching the highest expression in tumors with poorer outcome (as defined by the length of patients' survival) compared with normal livers. In sharp contrast, PLK2, PLK3, and PLK4 messenger RNA and protein expression gradually declined from nontumorous liver to HCC, with the lowest levels being detected in HCC with shorter survival. In liver tumors, PLK2‐4 down‐regulation was paralleled by promoter hypermethylation and/or loss of heterozygosity at the PLK2‐4 loci. Subsequent functional studies revealed that PLK1 inhibition led to suppression of cell growth in vitro , whereas opposite effects followed PLK2‐4 silencing in HCC cell lines. In particular, suppression of PLK1 resulted in a block in the G2/M phase of the cell cycle and in massive apoptosis of HCC cells in vitro regardless of p53 status. Conclusion: PLK1‐4 proteins are aberrantly regulated and possess different roles in human HCC, with PLK1 acting as an oncogene and PLK2‐4 being presumably tumor suppressor genes. Thus, therapeutic approaches aimed at inactivating PLK1 and/or reactivating PLK2‐4 might be highly useful in the treatment of human liver cancer. (H EPATOLOGY 2010.)